Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab plus phototherapy versus phototherapy in adults with progressive vitiligo
2022-002003-37Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anifrolumab in Vitiligo (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Mean variation in percentage of the Vitiligo Area Scoring Index score between baseline and week 36. Started Jan 2023; status: active.
02
Drugs
anifrolumab
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2022-002003-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002003-37.